Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 6/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592771 | 0.85 | JAK2 (0.44) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL4617227 | 0.83 | ALDH1A1 (0.57) | TSHRCYP3A4ALDH1A1CA2TDP1 | |
| SCHEMBL10183753 | 0.79 | HDAC4 (0.42) | JAK2ROCK2PRKCQPRKCDROCK1 | |
| SCHEMBL23113646 | 0.79 | CYP19A1 (0.41) | TSHRALDH1A1SCN10A | |
| SCHEMBL2442297 | 0.78 | ACHE (0.44) | MAPK1CYP3A4JAK2ROCK2PRKCQ | |
| SCHEMBL31476400 | 0.76 | TSHR (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL125232 | 0.76 | TSHR (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL29403060 | 0.76 | MAPK1 (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL111419 | 0.76 | MAPK1 (0.60) | TSHRMAPK1CYP3A4CASP1RECQL | |
| SCHEMBL29374282 | 0.76 | TSHR (0.60) | TSHRMAPK1CYP3A4CASP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240360132-A9 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240101559-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| CN-116874465-B | Pyrimidine compound and application thereof | 英矽智能科技(上海)有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008077548-A1 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | F2G LTD. (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| WO-2007119055-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007113557-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113558-A2 | QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | TSHR 541/4885MAPK1 650/4885CYP3A4 2960/4885 |
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | CDK1, CDK11A, CDK11B | TSHR 267/4885MAPK1 104/4885CYP3A4 1315/4885 |
| US-20240101559-A1 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | CDK1, CDK11B, CDK11A | TSHR 1822/4885MAPK1 106/4885CYP3A4 538/4885 |
| US-20240360132-A9 | TRICYCLIC KINASE INHIBITORS AND USES THEREOF | CDK1, CDK11B, CDK11A | TSHR 1822/4885MAPK1 106/4885CYP3A4 538/4885 |
| US-20080161302-A1 | N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus | NAT1, CYP1A2, CYP51A1 | TSHR 1872/4885MAPK1 657/4885CYP3A4 108/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | TSHR 3362/4885MAPK1 3874/4885CYP3A4 89/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | TSHR 581/4885MAPK1 507/4885CYP3A4 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.